Talya Richie
Nurse Practitioner · Ft Worth, TXNPI 1538793310
Payments from drug & device makers
Across 397 payments — averaging $18.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- AstraZeneca$897
- Dexcom, Inc.$704
- Novo Nordisk$685
- Lilly USA, LLC$665
- Sanofi-aventis U.S. LLC$485
- plus $3K from 37 others
What the payments were for
- Food & beverage$7,259100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 60 | $1,224 |
| AstraZeneca(2 entities) | 44 | $897 |
| Dexcom, Inc. | 37 | $704 |
| Novo Nordisk | 43 | $685 |
| Lilly USA, LLC | 39 | $665 |
| Sanofi-aventis U.S. LLC | 27 | $485 |
| AbbVie | 20 | $322 |
| Boehringer Ingelheim | 12 | $188 |
| Bayer | 11 | $178 |
| Mannkind Corporation | 8 | $162 |
| Amarin Pharma, Inc. | 8 | $144 |
| Amgen | 7 | $123 |
| Xeris Pharmaceuticals, Inc. | 7 | $120 |
| Medtronic | 6 | $115 |
| Cequr Corporation | 4 | $100 |
| Insulet Corporation | 4 | $99 |
| Pfizer | 6 | $97 |
| Alvogen Inc | 5 | $91 |
| Novartis | 3 | $79 |
| Corcept Therapeutics | 4 | $69 |
| Antares Pharma, Inc. | 4 | $69 |
| Radius Health, Inc. | 3 | $56 |
| Nevro Corp. | 3 | $56 |
| Amneal Pharmaceuticals LLC | 3 | $56 |
| BETA Bionics, Inc. | 4 | $55 |
| Merck | 3 | $44 |
| Tandem Diabetes Care, Inc. | 2 | $42 |
| Acella Pharmaceuticals, LLC | 2 | $33 |
| Intuity Medical Inc | 2 | $32 |
| Zealand Pharma US, Inc. | 2 | $31 |
| IBSA Pharma Inc. | 2 | $30 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| GRT US Holding, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Chiesi USA, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Teleflex LLC | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Halozyme Inc | 1 | $15 |
| Vivus LLC | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,270 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 177 | $194,181 |
| JardianceEmpagliflozin | 111 | $144,689 |
| TrulicityDulaglutide | 78 | $132,655 |
| OzempicSemaglutide | 73 | $106,022 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 58 | $70,103 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 58 | $63,821 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 74 | $56,960 |
| Tresiba Flextouch U-100Insulin Degludec | 70 | $54,428 |
| FarxigaDapagliflozin Propanediol | 53 | $50,740 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $38,204 |
| Humalog Kwikpen U-100Insulin Lispro | 50 | $21,610 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $15,821 |
| NovologInsulin Aspart | 37 | $14,394 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $12,570 |
| Cequr SimplicityBolus Insulin Pump, 200 Unit | 12 | $9,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $665 | $333,177277 claims |
| Boehringer IngelheimJardiance | $188 | $144,689111 claims |
| Novo NordiskOzempic, Novolog | $685 | $120,416110 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $485 | $70,10358 claims |
| AstraZenecaFarxiga | $897 | $50,74053 claims |
| Cequr CorporationCequr Simplicity | $100 | $9,44312 claims |
| AbbVieSynthroid, Armour Thyroid | $322 | $7,01169 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $56 | $953108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Ft Worth
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
- Onna FeuchterSouthlake$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.